We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+25.24%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$901M
AUM Growth
-$110M
Cap. Flow
-$189M
Cap. Flow %
-20.99%
Top 10 Hldgs %
74.5%
Holding
49
New
9
Increased
9
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$50.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$23.4M
3
TVTX icon
Travere Therapeutics
TVTX
+$19.8M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$19.7M
5
ZYME icon
Zymeworks
ZYME
+$19.3M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$62.5M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.5M
3
UTHR icon
United Therapeutics
UTHR
+$44.6M
4
ARRY
Array Biopharma Inc
ARRY
+$43.9M
5
PBYI icon
Puma Biotechnology
PBYI
+$34.9M

Sector Composition

Rank Sector Weight
1 Healthcare 89.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVLP
26
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$3.52M 0.39%
926,933
-573,067
-38% -$1.91M
KA
27
DELISTED
Kineta, Inc. Common Stock
KA
$3.42M 0.38%
25,000
– –
FPRX
28
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.3M 0.37%
547,712
-1,850,697
-77% -$17.7M
LRMR icon
29
Larimar Therapeutics
LRMR
$397M
$2.63M 0.29%
184,266
-74,974
-29% -$2M
STRM
30
DELISTED
Streamline Health Solutions
STRM
$197K 0.02%
8,676
– –
AKBA icon
31
Akebia Therapeutics
AKBA
$354M
– –
-131,531
Closed -$1.08M
ASND icon
32
PUT
Ascendis Pharma A/S
ASND
$16B
– –
-200,000
Closed -$23.5M
BCRX icon
33
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-5,955,762
Closed -$48.5M
CTMX icon
34
CytomX Therapeutics
CTMX
$675M
– –
-959,077
Closed -$10.3M
KYNB
35
PUT
Kyntra Bio
KYNB
$27.2M
– –
-8,000
Closed -$10.9M
KRYS icon
36
Krystal Biotech
KRYS
$10.1B
– –
-492,100
Closed -$16.2M
NVAX icon
37
CALL
Novavax
NVAX
$1.2B
– –
-225,000
Closed -$2.48M
NVAX icon
38
PUT
Novavax
NVAX
$1.2B
– –
-100,000
Closed -$1.1M
PBYI icon
39
Puma Biotechnology
PBYI
$404M
– –
-900,000
Closed -$34.9M
SLDB icon
40
CALL
Solid Biosciences
SLDB
$794M
– –
-13,333
Closed -$1.84M
SVRA icon
41
Savara
SVRA
$1.12B
– –
-660,366
Closed -$4.87M
UTHR icon
42
United Therapeutics
UTHR
$25.8B
– –
-379,832
Closed -$44.6M
CBAY
43
DELISTED
Cymabay Therapeutics
CBAY
– –
-998,841
Closed -$13.3M
ICPT
44
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-400,000
Closed -$44.7M
GBT
45
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-1,180,000
Closed -$62.5M
EPZM
46
DELISTED
Epizyme, Inc
EPZM
– –
-2,173,913
Closed -$26.9M
DERM
47
PUT
DELISTED
Dermira, Inc.
DERM
– –
-555,300
Closed -$7.52M
ARRY
48
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-200,000
Closed -$4.88M
ARRY
49
DELISTED
Array Biopharma Inc
ARRY
– –
-1,800,000
Closed -$43.9M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Great Point Partners held 49 positions worth $901M, down 11% from $1.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Great Point Partners withdrew a net $189M in Q2 2019, closing 19 positions and reducing 8 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $62.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Tricida, Inc. Common Stock worth $56.2M.

  • Great Point Partners's largest Q2 2019 buy was Tricida, Inc. Common Stock: 1,423,998 shares worth $56.2M.
  • Great Point Partners added most to Zymeworks in Q2 2019, an estimated $19.3M increase.
  • Great Point Partners's biggest Q2 2019 reduction was Five Prime Therapeutics, Inc., cutting an estimated $17.7M.
  • Great Point Partners fully exited Global Blood Therapeutics, Inc. in Q2 2019, selling an estimated $62.5M.
  • Great Point Partners's ten largest holdings make up 74% of its $901M portfolio in Q2 2019.
  • Great Point Partners opened 9 new positions and closed 19 in Q2 2019.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $901M.

Based on Great Point Partners's 13F filing for Q2 2019, filed 14 Aug 2019.